By targeting NLRP3 genetically or pharmacologically in a JAK2V617F mutant mouse model, we formally establish that NLRP3 potently promotes malignant thrombocytosis and, to a lesser extent, granulocytosis. Here, NLRP3 is linked to Increased total granulocyte count.